Muzzio M. Plasma Pharmokinetics of LMP400 in Rats and Dogs.
0%
Muzzio M. Plasma Pharmokinetics of LMP400 in Rats and Dogs.
Candeil L. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases.
Stenvang J. Targeting the topoisomerase I enzyme in cancer cells with acquired resistance to SN-38.
Jensen NF. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jandu H. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Burton JH. NCI Comparative Oncology Program Testing of Non-Camptothecin Indnoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Kummar S. Clinical and pharmacologic evaluation of two dosing schedules of indenothecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Tang SW. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Murai J. SLFN11 Blocks Stress Replication Forks Independently of ATR.
Pommier Y. Indotecan (LMP400), Imidotecan (LMP776) and LMP744: a new class of non-camptothecin TOP1 inhibitors selective for cancer cells with homologous recombination deficiencies and high SLFN11 expression.
Zoppoli G. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Aris S. Potentiation of the novel Topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor, AZD7762.
Gibson Oncology,LLC is composed of proven academic researchers and bio tech entrepreneurs who are excited to be developing effective and safer novel oncology drugs to treat resistant cancers with a focus on children.
